Population
2,059 cancer patients with varying diagnoses 6 months after discharge from a German rehabilitation clinic…
Comparison
Assessment of depression using the Patient… vs General population controls
Design
Cross-sectional
Follow-up
6 months post-discharge
Authors
Loading...
PHQ-9 may support adjusted depression screening across cancers; cross-sectional data leaves prospective validity and outcome prediction open.
The PHQ-9 is a reliable tool for assessing depression in cancer patients, and adjusting for age and gender is crucial for unbiased comparisons of depression burden across different cancer types.
Hinz et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: